Prices are updated after-hours

Health Technology 2017

Allena Pharmaceuticals, Inc.

ALNA | $0.075 -12.0%

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (431.58% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 9,156,242
http://www.allenapharma.com
Sec Filling | Patents | 83 employees

(United States) Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults; and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Newton, MA.

kidney diseases kidney stones treatment kidney

add to watch list Paper trade email alert is off

Athenex, Inc.

ATNX | $0.2031 -7.78% 1.9M

Health Technology

(0.0% 1d) (0.0% 1m) (-83.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (199.02% volume)
Earnings Calendar: 2022-10-27
Market Cap: $ 1,759,498
http://www.athenex.com
Sec Filling | Patents | 574 employees

(US) Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves in the sales and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

cancer tirbanibulin treatment

add to watch list Paper trade email alert is off

Jounce Therapeutics, Inc.

JNCE | $1.88 -2.59% -1.85% 0

Health Technology

(0.0% 1d) (0.0% 1m) (-1.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2023-05-04
Market Cap: $ 98,954,680
http://www.jouncetx.com
Sec Filling | Patents | 130 employees

(US) Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

cancer immunotherapy t-cell ceiling

add to watch list Paper trade email alert is off

ObsEva SA

OBSV | $0.1018 -15.52% -18.95% 8.2M

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (120.92% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 11,057,564
http://www.obseva.com
Sec Filling | Patents | 50 employees

(CH) ObsEva SA engages in the research and development of therapeutic treatments for woman's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.

pregnancy women treatment

add to watch list Paper trade email alert is off

Zealand Pharma A/S

ZEAL | $17.59 1.21% -4.21%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (1.2% 3d) (0.0% 7d) (22.0% volume)
Earnings Calendar:
Market Cap: $ 818,606,692
http://www.zealandpharma.com
Sec Filling | Patents | 179 employees

Zealand Pharma A/S is a biotechnology company that engages in the discovery, design and development of peptide based medicines. Its products include Soliqua and Lyxumia. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on October 19, 1998 and is headquartered in Soborg, Denmark.

add to watch list Paper trade email alert is off

Aileron Therapeutics, Inc.

ALRN | $4.88 2.74% 2.66% 100K

Health Technology

(0.0% 1d) (-13.5% 1m) (246.0% 1y) (0.0% 2d) (3.8% 3d) (4.0% 7d) (51.0% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 82,825,859
http://www.aileronrx.com
Sec Filling | Patents | 13 employees

Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.

cancer glass t-cell nash treatment ceiling

add to watch list Paper trade email alert is off

AnaptysBio, Inc.

ANAB | $19.25 0.37% 0.36% 390K

Health Technology

(0.0% 1d) (-10.8% 1m) (-8.1% 1y) (0.0% 2d) (0.5% 3d) (-3.0% 7d) (-0.43% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 515,189,309
http://www.anaptysbio.com
Sec Filling | Patents | 89 employees

(US) AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its products pipeline include ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

antibody

add to watch list Paper trade email alert is off

Apellis Pharmaceuticals, Inc.

APLS G | $49.84 2.3% 2.25% 1.2M

Health Technology

(0.0% 1d) (-15.4% 1m) (-41.0% 1y) (0.0% 2d) (2.5% 3d) (5.0% 7d) (5.13% volume)
Earnings Calendar: 2024-02-20
Market Cap: $ 6,009,794,370
http://www.apellis.com
Sec Filling | Patents | 235 employees

(United States) Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

immunotherapy autoimmunity treatment

add to watch list Paper trade email alert is off

argenx SE

ARGX | $375.0 -0.02% -0.02% 200K

Health Technology

(0.0% 1d) (-5.7% 1m) (-2.0% 1y) (0.0% 2d) (-0.0% 3d) (4.1% 7d) (-21.7% volume)
Earnings Calendar:
Market Cap: $ 22,286,654,625
http://www.argen-x.com
Sec Filling | Patents | 188 employees

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.

cancer antibody autoimmunity myeloid leukemia leukemia treatment

add to watch list Paper trade email alert is off

Avenue Therapeutics, Inc.

ATXI | $0.0949 -29.18% -41.2% 12M

Health Technology

(0.0% 1d) (-40.4% 1m) (-90.1% 1y) (0.0% 2d) (-30.8% 3d) (-30.8% 7d) (4299.79% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 4,200,337
http://www.avenuetx.com
Sec Filling | Patents | 4 employees

(US) Avenue Therapeutics, Inc. engages in acquiring, licensing, developing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, which is intended for the treatment of moderate to moderately severe post-operative pain. The company was founded on February 9, 2015 and is headquartered in New York, NY.

treatment kennedy’s disease

add to watch list Paper trade email alert is off

Biohaven Pharmaceutical Holding Company Ltd.

BHVN | News | $38.72 -2.25% -0.28% 970K

Health Technology

(0.0% 1d) (-31.2% 1m) (194.9% 1y) (0.0% 2d) (-2.2% 3d) (-0.7% 7d) (-53.44% volume)
Earnings Calendar:
Market Cap: $ 3,417,366,836
http://www.biohavenpharma.com
Sec Filling | Patents | 647 employees

(US) Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.

neurological

add to watch list Paper trade email alert is off

BeyondSpring, Inc.

BYSI | $2.46 7.42% 6.91% 97K

Health Technology

(0.0% 1d) (-32.7% 1m) (150.9% 1y) (0.0% 2d) (6.1% 3d) (27.2% 7d) (-13.36% volume)
Earnings Calendar: 2022-06-15
Market Cap: $ 95,753,254
http://www.beyondspringpharma.com
Sec Filling | Patents | 61 employees

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab for the treatment of NSCLC; and programmed cell death protein 1 and CTLA-4 antibodies to treat small cell lung cancer. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the University of Washington and the Fred Hutchinson Cancer Research Center. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.

cancer lung cancer antibody t-cell lungs clinical trials treatment ceiling

add to watch list Paper trade email alert is off

Deciphera Pharmaceuticals, Inc.

DCPH | $14.6 -0.48% -0.48% 320K

Health Technology

(0.0% 1d) (-1.3% 1m) (1.6% 1y) (0.0% 2d) (-0.3% 3d) (-0.3% 7d) (-5.76% volume)
Earnings Calendar: 2024-02-07
Market Cap: $ 1,179,680,905
http://www.deciphera.com
Sec Filling | Patents | 258 employees

Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.

cancer gastrointestinal tumor cells t-cell msa treatment ceiling

add to watch list Paper trade email alert is off

Denali Therapeutics Inc.

DNLI | $15.55 -3.48% -3.6% 940K

Health Technology

(0.0% 1d) (-21.7% 1m) (-36.2% 1y) (0.0% 2d) (-3.4% 3d) (-2.8% 7d) (-12.56% volume)
Earnings Calendar: 2023-11-02
Market Cap: $ 2,216,489,676
http://www.denalitherapeutics.com
Sec Filling | Patents | 261 employees

(US) Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

neurodegenerative

add to watch list Paper trade email alert is off

DermTech, Inc.

DMTK 4 | $0.616 3.81% 72K

Health Technology

(0.0% 1d) (-6.2% 1m) (-82.7% 1y) (0.0% 2d) (-1.6% 3d) (-4.7% 7d) (-57.49% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 21,328,041
http://www.dermtech.com
Sec Filling | Patents | 116 employees

DermTech, Inc. is a genomics company in dermatology, which engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate the early detection of skin cancers, assesses inflammatory diseases, and customizes drug treatments. Its products include adhesive skin collection kit, pigmented lesion assay, nevome, and carcinome. The company was founded in 1995 and is headquartered in La Jolla, CA.

skin cancer genomic diagnostics treatment

add to watch list Paper trade email alert is off

Co-Diagnostics, Inc.

CODX | $1.17 1.74% 1.71% 33K

Health Technology

(0.0% 1d) (2.2% 1m) (-15.6% 1y) (0.0% 2d) (-0.9% 3d) (-0.9% 7d) (221.11% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 36,573,812
http://www.codiagnostics.com
Sec Filling | Patents | 23 employees

(US) Co-Diagnostics, Inc. engages in the development, manufacture, and marketing of diagnostics technology. It offers design services, vector control, equipment, diagnostic, and research solutions. The company was founded by Brent C. Satterfield and Dwight H. Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

diagnostics

add to watch list Paper trade email alert is off

Forte Biosciences, Inc.

FBRX 4 | $0.711 -3.74% -4.03% 14K

Health Technology

(0.0% 1d) (1.5% 1m) (-32.1% 1y) (0.0% 2d) (-2.7% 3d) (-1.4% 7d) (204.19% volume)
Earnings Calendar: 2022-11-07
Market Cap: $ 25,876,761
http://www.fortebiorx.com
Sec Filling | Patents | 29 employees

(US) Forte Biosciences, Inc. engages in the development of biopharmaceutical products. It is a clinical stage dermatology company focuses in the treatment of inflammatory skin diseases. It offers FB-401, a live bio-therapeutic product. The company was founded by Paul A. Wagner in 2017 and is headquartered in Torrance, CA.

skin treatment

add to watch list Paper trade email alert is off

G1 Therapeutics, Inc.

GTHX | $3.98 -5.01% -5.28% 340K

Health Technology

(0.0% 1d) (-7.0% 1m) (62.2% 1y) (0.0% 2d) (-4.8% 3d) (-2.9% 7d) (-3.12% volume)
Earnings Calendar: 2024-02-28
Market Cap: $ 207,892,852
http://www.g1therapeutics.com
Sec Filling | Patents | 104 employees

(US) G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

cancer treatment

Drugs

Cosela (trilaciclib)

add to watch list Paper trade email alert is off

InflaRx N.V.

IFRX | $1.355 -0.37% -0.37% 71K

Health Technology

(0.0% 1d) (-11.7% 1m) (-70.9% 1y) (0.0% 2d) (-6.8% 3d) (0.7% 7d) (Infinity% volume)
Earnings Calendar: 2024-03-20
Market Cap: $ 79,786,834
http://www.inflarx.de
Sec Filling | Patents | 45 employees

(DE) InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products include IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

add to watch list Paper trade email alert is off

Immuron Limited

IMRN | $2.46 4.94% 1.3K

Health Technology

(0.0% 1d) (-9.8% 1m) (30.0% 1y) (0.0% 2d) (1.2% 3d) (7.8% 7d) (-32.56% volume)
Earnings Calendar:
Market Cap: $ 14,021,899
http://www.immuron.com
Sec Filling | Patents | 11 employees

(AU) Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. It operates through the following segments: Research and Development, and HyperImmune Products.The Research and Development segment involves the R&D projects performed in Australia, Israel, and United States. The HyperImmune Products segment comprises of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.

antibody immunotherapy israel treatment

add to watch list Paper trade email alert is off